Understanding the human body is a team effort. That's where the Yachtel group comes in.

Researchers at Yachtolt have been delving into the secrets of probiotics for 90 years.

Yacold also partners with nature portfolio to advance gut microbiome science through the global grants for gut health, an investigator-led research program.

To learn more about Yachtolt, visit yawcult.co.

J-P. That's Y-A-K-U-L-T dot CO.J-P. When it comes to a guide for your gut, count on Yacult.

This is Scientific Americans' 60-second science. I'm Steve Merski. Got a minute?

Medical marijuana is now available in 28 states. But a big obstacle to research on marijuana as medicine is that it's listed by the federal government on what's called Schedule 1. Assignment to Schedule 1 means that the Food and Drug Administration does not

recognize a legitimate medical purpose to a substance. At a session on medical marijuana at the

annual meeting of the American Association for the Advancement of Science on February 19th,

I asked researcher Ryan Vandrie of the Johns Hopkins University School of Medicine about getting

marijuana off of the list of Schedule I substances.

Well, it can't come off of Schedule 1 to a different schedule until the traditional drug development work has been done.

And I don't think the traditional drug development work really can be done

while it's Schedule 1. It just makes large phase 3 trials in hospital-based programs near impossible.

It's a catch-22. So I think the only way to really get around that is kind of two paths. One,

you just unschedule it completely. Alcohol is not scheduled, for example,

and so that's the pathway that some of the states have gone just making it available,

or treating as a, like, a botanical herbal product. The other way would be to kind of wait

until we get more targeted specific products. So not whole plant

cannabis, but maybe more specific formulations with specific cannabinoid profiles would be the other

way.

Is your life being easier with it all?

...